Leading medical journals propose mandate on clinical data sharing

The International Committee of Medical Journal Editors (ICMJE) proposes new rules that will require authors to share clinical trial data as a prerequisite for their manuscripts to be considered for publication. The goal is to improve the benefit to society from the efforts of patients who volunteer to participate in clinical trials. The ICMJE proposal is outlined in an editorial published simultaneously today in Annals of Internal Medicine and 13 other ICMJE member journals.

"Enabling responsible data sharing is a major endeavor that will affect the fabric of how clinical trials are planned and conducted and how their data are used," writes lead author Darren Taichman, MD, PhD, Secretary, ICMJE and Executive Deputy Editor of Annals of Internal Medicine. "By changing the requirements of the manuscripts we will consider for publication in our journals, editors can help foster this endeavor."

The ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention to study the cause-and-effect relationship between a health-related intervention and a health outcome. The ICMJE believes there is an ethical obligation to share data generated by interventional clinical trials because participants put themselves at risk. They say that sharing data should increase confidence and trust in the conclusions drawn from clinical trials, enable independent confirmation of results, and foster the development and testing of new hypotheses. If done well, data sharing will benefit patients, investigators, sponsors, and society.

The ICMJE is seeking and will consider feedback before it adopts new data sharing requirements. Comments are welcome at http://www.icmje.org/ and should be received by April 2016. It anticipates that new data-sharing requirement will go into effect for clinical trials that begin to enroll participants beginning 1 year after the ICMJE adopts the new policy.

About the International Committee of Medical Journal Editors
The ICMJE is a small working group of general medical journal editors whose participants meet annually and fund their own work on the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.

About Annals of Internal Medicine
Annals of Internal Medicine is one of the most widely cited and influential medical journals in the world, with an impact factor of 17.810 - the highest of any specialty journal in its category. Annals' mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. Established in 1927, Annals is the flagship journal of the American College of Physicians (ACP).

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]